43P - Are tumoural microRNA (miR) a reliable tool in predicting chemosensitivity and prognosis in advanced non-small cell lung cancer (NSCLC)? A prospecti...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Thierry Berghmans
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors T. Berghmans1, L. Ameye2, M. Paesmans3, J. Lafitte4, A. Meert5, A. Scherpereel4, I. CsToth5, T. Dernies5, N. Leclercq5, J. Sculier5
  • 1Intensive Care And Oncological Emergencies & Thoracic Oncology, Institut Jules Bordet, 1000 - Brussels/BE
  • 2Data Centre, Institut Jules Bordet, Brussels/BE
  • 3Data Centre, Institute Jules Bordet, Brussels/BE
  • 4Pneumology, CHU Calmette, Lille/FR
  • 5Intensive Care And Oncological Emergencies & Thoracic Oncology, Institut Jules Bordet, Brussels/BE

Abstract

The activity of cisplatin chemotherapy for NSCLC is not individually predictable. In a prospective study (Berghmans et al, Lung Cancer 2013), we found two signatures predicting either chemosensitivity (predictive, 2 miR) either survival (prognostic, 4 miR), in a group of 38 patients treated with cisplatin-vinorelbine. We are presenting the results of a validation study.